Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Prevalence of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease (ETENDARD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00434902
Recruitment Status : Unknown
Verified November 2012 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was:  Active, not recruiting
First Posted : February 14, 2007
Last Update Posted : December 19, 2012
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
Recent data show that pulmonary hypertension (PH), defined by a tricuspid regurgitation jet (TRJ) velocity > or equal at 2.5m/s on Doppler echocardiography, is present in about 30% of adults with sickle cell disease (SCD) and is associated with poor prognosis. However in SCD the occurrence of PH (defined by mean pulmonary arterial pressure (mPAP)> or equal at 25 mmHg) is related to at least 3 mechanisms: PH due to hyperkinetic state with high cardiac output (CO) but normal pulmonary vascular resistance (PVR <160 dynes), or postcapillary PH (pulmonary capillary wedge pressure PCWP >15 mmHg), or precapillary pulmonary arterial hypertension (PAH) defined by mPAP > or equal at 25 mmHg, PCWP< or equal at 15 mmHg and PVR > or equal at 160 dynes.The aim of this study is to evaluate in a French population of adults with sickle cell disease the characteristics, prevalence and prognosis of pulmonary hypertension.

Condition or disease
Sickle Cell Disease

Detailed Description:

Consecutive adult patients with sickle cell disease (SCD) had a Doppler echocardiography to evaluate if they had a suspected pulmonary hypertension (PH) on the basis of a tricuspid regurgitation jet (TRJ) velocity > or equal at 2.5m/s. In this case, a right heart catheterization was performed to confirm or not this diagnosis and its mechanisms. Each included patient was followed every year for 3 years: during each visit, a clinical evaluation was obtained and a Doppler echocardiography. In case of emergence of a suspected PH, a right heart catheterization was performed to confirm or not this diagnosis and its mechanisms.

Three groups of patients were defined: no PH, precapillary PH, and a third group including post-capillary PH and hyperkinetic state. These groups were well defined on the basis of the results of th Doppler echocardiography and right heart catheterisation.

Characteristics of patients and their prognosis were evaluated in each group.

In the same, way, biological study is planned to evaluate some biological markers of the mechanism of PH, and prognostic factors.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 700 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Characteristics, Prevalence and Prognosis of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease: Study ETENDARD.
Study Start Date : February 2007
Actual Primary Completion Date : March 2009
Estimated Study Completion Date : December 2012






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult Patients With Sickle Cell Disease
Criteria

Inclusion Criteria:

  • Homozygous SS sickle cell disease
  • Male or female > 18 years of age
  • VOC (Vaso-Occlusive crisis) or ACS (Acute chest syndrome)within 6 weeks of inclusion ("Stable state")
  • Signed written Informed consent

Exclusion Criteria:

  • Creatinine clearance < 30 ml/mn
  • prothrombin ratio < 50%
  • Severe pneumopathy and TLC (Total lung capacity) < 70%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00434902


Locations
Layout table for location information
France
Hôpital Antoine Béclère
Clamart, France, 92141
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Gerald SIMONNEAU, MD Hôpital Antoine Béclère, CLAMART
Principal Investigator: Frederic Galacteros, MD Hôpital Henri Mondor, Creteil
Study Director: Serge ADNOT, MD Hôpital Henri Mondor, CRETEIL
Study Director: Bernard MAITRE, MD Hopital Henri Mondor, CRETEIL
Study Director: Marc HUMBERT, MD Hôpîtal Antoine Béclere, CLAMART
Study Director: Robert GIROT, MD Hôpital Tenon, PARIS
Study Director: François LIONNET, MD Hôpital TENON, PARIS
Study Director: Françoise DRISS, MD Hôpital Bicêtre, KREMLIN BICETRE
Study Chair: Olivier LAMBOTTE, MD Hôpital Bicêtre, KREMLIN BICETRE
Study Director: Jocelyn INAMO, MD CHU Fort de France
Study Director: Gylna LOKO, MD CHU Fort de France
Study Director: Olivier SITBON, MD Hôpital Antoine Béclère, CLAMART
Study Director: Xavier Jaïs, MD Hôpital Antoine Béclère, CLAMART
Study Chair: Anoosha Habibi, MD Hôpital Henri Mondor, CRETEIL
Study Chair: Dora Bachir, MD Hôpital Henri Mondor, CRETEIL
Study Chair: Laurent SAVALE, MD Hopital Henri Mondor, CRETEIL
Study Chair: Saadia Eddahibi, MD Hôpital Henri Mondor, CRETEIL
Study Chair: Gilles Garcia, MD Hopital Antoine Béclère, CLAMART
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00434902    
Other Study ID Numbers: PO51082
AOM-05037
First Posted: February 14, 2007    Key Record Dates
Last Update Posted: December 19, 2012
Last Verified: November 2012
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Doppler Echocardiography
Pulmonary hypertension
Sickle cell disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Hypertension
Anemia, Sickle Cell
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn